Bulletin from the Annual General Meeting in Implantica AG
Today, April 16, 2021, the annual general meeting (the “AGM”) of Implantica AG (publ) was held in Vaduz. The general meeting resolved to adopt all of the board of directors’ resolution proposals. A summary of the resolutions adopted at the general meeting is set out below.
The general meeting adopted the annual report 2020 consisting of the statutory financial statements and the consolidated financial statements of Implantica AG for the financial year 2020 and resolved, in accordance with the board of directors’ proposal, to carry forward the net loss for the financial year 2020.
The general meeting resolved to discharge the members of the board of directors, the executive management and the auditors from liability for their services in the business year 2020.
The general meeting resolved to re-elect Liselott Kilaas, Johan Bojs, Tomas Puusepp, Robert Frigg, Klaus Neftel and Stephan Siegenthaler as board members for a term of office until completion of the next AGM of shareholders. Liselott Kilaas was also re-elected as chairman and Johan Bojs was re-elected as vice-chairman of the board of directors until the end of the next annual general meeting.
The general meeting resolved to re-elect Johan Bojs as chairman and Klaus Neftel as member of the nomination and remuneration committee until completion of the next AGM.
The general meeting resolved to re-elect KPMG (Liechtenstein) AG, Aulestrasse 2, 9490 Vaduz, Liechtenstein as auditor for the financial year 2021.
The general meeting resolved to approve the total remuneration of the board of directors of EUR 145 thousand and of the executive management of EUR 513 thousand for the financial year 2020. The total remuneration includes fixed compensation, pension contributions and the long-term share-based incentive plan.
The general meeting resolved to authorize the board of directors to, with or without deviation from the shareholders’ preferential rights, resolve on new share issues. The objective of the authorization is to provide the board of directors with flexibility in its work to ensure that the company can procure capital for the financing of the operations in an appropriate manner, to enable business or company acquisitions and to enable a broadening of the company’s shareholder base. In line herewith, the general meeting adopted the board’s resolution to amend Article 4a para. 1 of the Articles of Association.
The minutes of the annual general meeting with information regarding each resolution proposal adopted at the general meeting will be available at www.implantica.com.
For further information, please contact:
Nicole Pehrsson, Investor Relations
Telephone (CH): +41 (0)79 335 09 49
Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.
The company's Certified Adviser is FNCA Sweden AB, +46 (0)8 528 00 399, firstname.lastname@example.org
The information was sent for publication, through the agency of the contact person set out above, on April 16, 2021 at 02:00 p.m. CET.
Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica’s lead product, RefluxStop™, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energising platform designed to power remote controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit www.implantica.com for further information.